NAV

Palmidrol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Palmidrol
DrugBank Accession Number
DB14043
Background

A cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection. Palmidrol is available for human use as a supplement (400 mg capsules) and as food for medical purposes In Italy and Spain (300 mg and 600 mg tablets).

Type
Small Molecule
Groups
Experimental, Nutraceutical
Structure
Similar Structures
Weight
Average: 299.4919
Monoisotopic: 299.282429433
Chemical Formula
C18H37NO2
Synonyms
  • Hydroxyethylpalmitamide
  • Monoethanolamine palmitic acid amide
  • N-(2-Hydroxyethyl)palmitamide
  • N-hexadecanoylethanolamine
  • N-palmitoylethanolamine
  • Palmidrol
  • palmidrolum
  • Palmitamide MEA
  • Palmitic acid monoethanolamide
  • Palmitinsaeure-beta-hydroxyethylamid
  • Palmitoyl ethanolamide
  • Palmitoyl-EA
  • Palmitoylethanolamide
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when Palmidrol is combined with 1,2-Benzodiazepine.
AcebutololThe risk or severity of Tachycardia can be increased when Palmidrol is combined with Acebutolol.
AcetazolamideThe risk or severity of adverse effects can be increased when Palmidrol is combined with Acetazolamide.
AcetophenazineThe risk or severity of adverse effects can be increased when Palmidrol is combined with Acetophenazine.
AclidiniumThe risk or severity of Tachycardia and drowsiness can be increased when Aclidinium is combined with Palmidrol.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Palmdrol prodes

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as carboximidic acids. These are organic acids with the general formula RC(=N)-OH (R=H, organic group).
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboximidic acids and derivatives
Sub Class
Carboximidic acids
Direct Parent
Carboximidic acids
Alternative Parents
Propargyl-type 1,3-dipolar organic compounds / Alkanolamines / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Alcohol / Aliphatic acyclic compound / Alkanolamine / Carboximidic acid / Hydrocarbon derivative / Organic 1,3-dipolar compound / Organic nitrogen compound / Organic oxygen compound / Organonitrogen compound / Organooxygen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
N-(long-chain-acyl)ethanolamine, endocannabinoid, N-(saturated fatty acyl)ethanolamine (CHEBI:71464) / N-acyl ethanolamines (endocannabinoids) (LMFA08040013)
Affected organisms
Not Available

Chemical Identifiers

UNII
6R8T1UDM3V
CAS number
544-31-0
InChI Key
HXYVTAGFYLMHSO-UHFFFAOYSA-N
InChI
InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)
IUPAC Name
N-(2-hydroxyethyl)hexadecanamide
SMILES
CCCCCCCCCCCCCCCC(=O)NCCO

References

General References
Not Available
Human Metabolome Database
HMDB0002100
KEGG Drug
D08328
KEGG Compound
C16512
ChemSpider
4509
BindingDB
29083
RxNav
2001986
ChEBI
71464
ChEMBL
CHEMBL417675
ZINC
ZINC000008035017
Wikipedia
Palmitoylethanolamide

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
4CompletedTreatmentChronic Pain1
3CompletedTreatmentMigraine1
2Active Not RecruitingSupportive CareChemotherapy Induced Peripheral Neuropathy (CIPN) / Hematopoietic and Lymphoid System Neoplasm / Malignant Solid Neoplasms1
2CompletedTreatmentGilles de la Tourette's Syndrome1
2RecruitingDiagnosticDepression, Bipolar / Major Depressive Disorder (MDD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00136 mg/mLALOGPS
logP5.74ALOGPS
logP4.98Chemaxon
logS-5.3ALOGPS
pKa (Strongest Acidic)15.46Chemaxon
pKa (Strongest Basic)-1.3Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area49.33 Å2Chemaxon
Rotatable Bond Count16Chemaxon
Refractivity90.09 m3·mol-1Chemaxon
Polarizability40.05 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-01ot-9550000000-2a81c82885f59140f22b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-9237000000-e820748d919e8d9a8373
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000t-0090000000-d0c6305114df937642e2
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-9220000000-7d9da270b522cdcac64e
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-001v-4090000000-8b3fc78de234fe27320d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-000f-9250000000-856397c1c8aea0111d0e
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-052f-9100000000-b869cbfb9c3d1634cfac
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-208.6633712
predicted
DarkChem Lite v0.1.0
[M-H]-208.5555712
predicted
DarkChem Lite v0.1.0
[M-H]-209.4893712
predicted
DarkChem Lite v0.1.0
[M-H]-174.03604
predicted
DeepCCS 1.0 (2019)
[M+H]+208.2223712
predicted
DarkChem Lite v0.1.0
[M+H]+208.7295712
predicted
DarkChem Lite v0.1.0
[M+H]+208.7383712
predicted
DarkChem Lite v0.1.0
[M+H]+177.69026
predicted
DeepCCS 1.0 (2019)
[M+Na]+208.1208712
predicted
DarkChem Lite v0.1.0
[M+Na]+208.1745712
predicted
DarkChem Lite v0.1.0
[M+Na]+207.8614712
predicted
DarkChem Lite v0.1.0
[M+Na]+186.65744
predicted
DeepCCS 1.0 (2019)

Drug created at May 22, 2018 17:59 / Updated at February 21, 2021 18:54